JP2022526159A5 - - Google Patents

Info

Publication number
JP2022526159A5
JP2022526159A5 JP2021557206A JP2021557206A JP2022526159A5 JP 2022526159 A5 JP2022526159 A5 JP 2022526159A5 JP 2021557206 A JP2021557206 A JP 2021557206A JP 2021557206 A JP2021557206 A JP 2021557206A JP 2022526159 A5 JP2022526159 A5 JP 2022526159A5
Authority
JP
Japan
Prior art keywords
tki
egfr
egfr tki
generation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/058729 external-priority patent/WO2020201097A1/en
Publication of JP2022526159A publication Critical patent/JP2022526159A/ja
Publication of JP2022526159A5 publication Critical patent/JP2022526159A5/ja
Priority to JP2025087802A priority Critical patent/JP2025131642A/ja
Pending legal-status Critical Current

Links

JP2021557206A 2019-03-29 2020-03-27 非小細胞肺がんの治療に使用するためのオシメルチニブ Pending JP2022526159A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087802A JP2025131642A (ja) 2019-03-29 2025-05-27 非小細胞肺がんの治療に使用するためのオシメルチニブ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825867P 2019-03-29 2019-03-29
US62/825,867 2019-03-29
PCT/EP2020/058729 WO2020201097A1 (en) 2019-03-29 2020-03-27 Osimertinib for use in the treatment of non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087802A Division JP2025131642A (ja) 2019-03-29 2025-05-27 非小細胞肺がんの治療に使用するためのオシメルチニブ

Publications (2)

Publication Number Publication Date
JP2022526159A JP2022526159A (ja) 2022-05-23
JP2022526159A5 true JP2022526159A5 (cg-RX-API-DMAC7.html) 2023-03-31

Family

ID=70224330

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557206A Pending JP2022526159A (ja) 2019-03-29 2020-03-27 非小細胞肺がんの治療に使用するためのオシメルチニブ
JP2025087802A Pending JP2025131642A (ja) 2019-03-29 2025-05-27 非小細胞肺がんの治療に使用するためのオシメルチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087802A Pending JP2025131642A (ja) 2019-03-29 2025-05-27 非小細胞肺がんの治療に使用するためのオシメルチニブ

Country Status (11)

Country Link
US (1) US12465608B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946346A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022526159A (cg-RX-API-DMAC7.html)
KR (2) KR102992349B1 (cg-RX-API-DMAC7.html)
CN (1) CN113645976A (cg-RX-API-DMAC7.html)
AU (2) AU2020250832A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133766A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192552A1 (cg-RX-API-DMAC7.html)
MA (1) MA55508A (cg-RX-API-DMAC7.html)
MX (1) MX2021011810A (cg-RX-API-DMAC7.html)
WO (1) WO2020201097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259147A4 (en) * 2020-12-11 2024-10-23 Erasca, Inc. Combination therapies for the treatment of cancer
CN117098537A (zh) * 2020-12-11 2023-11-21 医睿世康药业研发公司 用于癌症治疗的联合疗法
US20240309363A1 (en) * 2021-01-12 2024-09-19 Georgia Tech Research Corporation Combination therapeutics for treatment of proliferative disorders
CN119768173A (zh) * 2022-09-01 2025-04-04 齐鲁制药有限公司 一种egfr激酶抑制剂的用途
TW202515577A (zh) * 2023-06-27 2025-04-16 日商大鵬藥品工業股份有限公司 患有具有egfr畸變的非小細胞肺癌之個體的治療方法
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
WO2006068826A2 (en) 2004-12-21 2006-06-29 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007067506A2 (en) 2005-12-05 2007-06-14 Smithkline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
EP2040546A4 (en) 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
CA2663599A1 (en) * 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2012501654A (ja) 2008-09-05 2012-01-26 アビラ セラピューティクス, インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
CA2778265A1 (en) 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
AU2014324478A1 (en) * 2013-09-30 2016-05-05 Amgen, Inc. Nucleic acid biomarker and use thereof
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN107530434A (zh) * 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
WO2017200016A1 (ja) 2016-05-17 2017-11-23 公益財団法人がん研究会 Egfr-tki耐性を獲得した肺癌の治療薬
WO2018102827A1 (en) 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
MA51823A (fr) 2018-02-12 2021-05-19 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
Diaz-Rubio et al. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Mauer et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
US20060009418A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
Park et al. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
Tewes et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
JP2024125139A (ja) アズブジンを含む抗腫瘍医薬組成物
JP2005508896A5 (cg-RX-API-DMAC7.html)
KR20210068344A (ko) 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2024539476A5 (cg-RX-API-DMAC7.html)
Ruiter et al. PT2. 12.03 Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1
KR20170055536A (ko) 흡연자에서의 비-소세포 폐암 치료용 카보플라틴 및 파클리탁셀과 병용되는 벨리파립
US20080125447A1 (en) Combination Therapy
AU2006264620B2 (en) Combination therapy of cancer with AZD2171 and gemcitabine
US20070135462A1 (en) Combination therapy
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
US20240173323A1 (en) Combination therapy for cancer treatment
Koukourakis et al. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy
김현지 Treatment Efficacy and Toxicity of Targeted Combination Therapy in Elderly Patients with Colon Cancer
Vinitsky et al. CTP-08. Efficacy and tolerability of mirdametinib (PD-0325901) in children, adolescents, and young adults with recurrent/progressive low-grade glioma: update from the SJ901 (NCT04923126) phase 1/2 clinical trial
Han et al. CTP-06. Molecular insights into response and resistance in children with relapsed/refractory brain tumors on ribociclib combination therapy: results from SJDAWN
Miralles et al. 5PSQ-066 Experience of use of axitinib in clinical practice